- Home
- CTOR vs FBIO Comparison
CTOR vs FBIO Comparison
Compare CTOR & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- FBIO
- Stock Information
- Founded
- CTOR 2021
- FBIO 2006
- Country
- CTOR United States
- FBIO United States
- Employees
- CTOR N/A
- FBIO N/A
- Industry
- CTOR
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- FBIO Health Care
- Exchange
- CTOR NYSE
- FBIO Nasdaq
- Market Cap
- CTOR 52.2M
- FBIO 49.1M
- IPO Year
- CTOR N/A
- FBIO N/A
- Fundamental
- Price
- CTOR $0.87
- FBIO $1.69
- Analyst Decision
- CTOR Strong Buy
- FBIO Strong Buy
- Analyst Count
- CTOR 2
- FBIO 3
- Target Price
- CTOR $4.50
- FBIO $21.00
- AVG Volume (30 Days)
- CTOR 65.0K
- FBIO 144.5K
- Earning Date
- CTOR 05-21-2025
- FBIO 05-19-2025
- Dividend Yield
- CTOR N/A
- FBIO N/A
- EPS Growth
- CTOR N/A
- FBIO N/A
- EPS
- CTOR N/A
- FBIO N/A
- Revenue
- CTOR N/A
- FBIO $57,675,000.00
- Revenue This Year
- CTOR N/A
- FBIO $63.20
- Revenue Next Year
- CTOR N/A
- FBIO $66.70
- P/E Ratio
- CTOR N/A
- FBIO N/A
- Revenue Growth
- CTOR N/A
- FBIO N/A
- 52 Week Low
- CTOR $0.55
- FBIO $1.33
- 52 Week High
- CTOR $49.00
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- FBIO 52.97
- Support Level
- CTOR N/A
- FBIO $1.67
- Resistance Level
- CTOR N/A
- FBIO $1.84
- Average True Range (ATR)
- CTOR 0.00
- FBIO 0.09
- MACD
- CTOR 0.00
- FBIO 0.01
- Stochastic Oscillator
- CTOR 0.00
- FBIO 58.54
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.